ATE244574T1 - Verfahren zur verbesserten funktionelle erholung der motorische koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns - Google Patents

Verfahren zur verbesserten funktionelle erholung der motorische koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns

Info

Publication number
ATE244574T1
ATE244574T1 AT97917532T AT97917532T ATE244574T1 AT E244574 T1 ATE244574 T1 AT E244574T1 AT 97917532 T AT97917532 T AT 97917532T AT 97917532 T AT97917532 T AT 97917532T AT E244574 T1 ATE244574 T1 AT E244574T1
Authority
AT
Austria
Prior art keywords
morphogens
nervous system
central nervous
morphogen
ischemia
Prior art date
Application number
AT97917532T
Other languages
English (en)
Inventor
Marc F Charette
Seth P Finklestein
Original Assignee
Curis Inc
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24485972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE244574(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Curis Inc, Gen Hospital Corp filed Critical Curis Inc
Application granted granted Critical
Publication of ATE244574T1 publication Critical patent/ATE244574T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Control Of Electric Motors In General (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
  • Protection Of Generators And Motors (AREA)
AT97917532T 1996-03-22 1997-03-21 Verfahren zur verbesserten funktionelle erholung der motorische koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns ATE244574T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62044496A 1996-03-22 1996-03-22
PCT/US1997/004177 WO1997034626A1 (en) 1996-03-22 1997-03-21 Methods for enhancing functional recovery following central nervous system ischemia or trauma

Publications (1)

Publication Number Publication Date
ATE244574T1 true ATE244574T1 (de) 2003-07-15

Family

ID=24485972

Family Applications (2)

Application Number Title Priority Date Filing Date
AT97917532T ATE244574T1 (de) 1996-03-22 1997-03-21 Verfahren zur verbesserten funktionelle erholung der motorische koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns
AT03010945T ATE493141T1 (de) 1996-03-22 1997-03-21 Verfahren zur verbesserten funktionellen erholung der motorischen koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT03010945T ATE493141T1 (de) 1996-03-22 1997-03-21 Verfahren zur verbesserten funktionellen erholung der motorischen koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns

Country Status (11)

Country Link
US (4) US6407060B1 (de)
EP (3) EP0894004B2 (de)
JP (2) JP4847634B2 (de)
KR (1) KR20000064752A (de)
CN (1) CN1181885C (de)
AT (2) ATE244574T1 (de)
AU (2) AU725341B2 (de)
CA (2) CA2249368A1 (de)
DE (2) DE69740089D1 (de)
ES (1) ES2201287T5 (de)
WO (2) WO1997034626A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
DK1378572T3 (da) 1993-05-12 2007-02-05 Genetics Inst Llc BMP-11-sammensætninger
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
WO1998020889A1 (en) * 1996-11-15 1998-05-22 Creative Biomolecules Inc Morphogen peptide-induced regeneration of sense perceptory tissues
JP5033276B2 (ja) * 1997-05-05 2012-09-26 ストライカー コーポレイション 急性腎不全の治療
EP2309261A1 (de) * 1997-05-30 2011-04-13 Stryker Corporation Verfahren zur Beurteilung von Gewebemorphogenese und- aktivität
AU1706499A (en) * 1997-12-04 1999-06-16 Curis, Inc. Maintenance of smooth muscle integrity by morphogenic proteins
US20030170213A1 (en) * 1998-01-23 2003-09-11 Marc F. Charette Methods and compositions for enhancing cognitive function using morphogenic proteins
US7147839B2 (en) 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity
DE19837230A1 (de) * 1998-08-17 2000-03-09 Jean Krutmann Neurotrophin-4 zur Behandlung von Tumoren neuroektodermalen Ursprungs
CA2380953A1 (en) * 1999-08-18 2001-02-22 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
US6749850B1 (en) 1999-08-18 2004-06-15 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
US7060676B2 (en) 1999-12-20 2006-06-13 Trustees Of Tufts College T. cruzi-derived neurotrophic agents and methods of use therefor
US6855690B2 (en) 2000-06-01 2005-02-15 Children's Medical Center Corporation Methods and compositions for treating ocular disorders
JP2003534385A (ja) * 2000-06-01 2003-11-18 チルドレンズ メディカル センター コーポレーション 被験者の神経に有益な効果をもたらす方法および組成物
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
EP1401495A4 (de) * 2001-06-01 2005-11-23 Xcyte Therapies Inc T-zelleninduzierte gewebereparatur und regeneration
US20060259014A1 (en) 2002-05-22 2006-11-16 Surgimark, Inc. Aspirator sleeve and suction handle
US20040229292A1 (en) * 2002-11-26 2004-11-18 Sebastiano Cavallaro Use of FGF-18 in the diagnosis and treatment of memory disorders
ATE459370T1 (de) 2002-11-26 2010-03-15 Biocon Ltd Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen
MXPA05012080A (es) 2003-05-08 2006-02-22 Xcyte Therapies Inc Generacion y aislamiento de celulas t especificas al antigeno.
CA2571218C (en) 2004-06-17 2015-11-03 William D. Carlson Tdf-related compounds and analogs thereof
EP2453024B1 (de) 2004-06-21 2017-12-06 The Board of Trustees of The Leland Stanford Junior University Differenziell exprimierte Gene und Leitungsbahnen bei bipolarer Störung und/oder schwerer depressiver Erkrankung
WO2006012365A2 (en) * 2004-07-20 2006-02-02 University Of Maryland Protease inhibitor
EP1782821A4 (de) * 2004-07-29 2009-11-11 Anges Mg Inc Arzneimittel und verfahren zur verbesserung der gehirnfunktion
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
GB0425625D0 (en) * 2004-11-22 2004-12-22 Royal College Of Surgeons Ie Treatment of disease
HUE026634T2 (en) 2005-09-20 2016-07-28 Thrasos Innovation Inc TDF-related compounds and analogues thereof
US20090019557A1 (en) 2005-11-12 2009-01-15 Huda Akil Fgf2-related methods for diagnosing and treating depression
AU2007234612B2 (en) * 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
EP2121142B1 (de) * 2007-01-25 2013-04-03 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH Verwendung von gdf-5 zur verbesserung oder aufrechterhaltung des aussehens der haut
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
JP5323832B2 (ja) 2007-08-07 2013-10-23 アドバンスト・テクノロジーズ・アンド・リジェネレイティブ・メディスン・エルエルシー 酸性水溶液中にｇｄｆ−５を含むタンパク質製剤
CA2720845A1 (en) * 2008-04-14 2009-10-22 Advanced Technologies And Regenerative Medicine, Llc Liquid buffered gdf-5 formulations
EP2396026A2 (de) * 2009-02-12 2011-12-21 Stryker Corporation Zusammensetzungen und verfahren für die minimal invasive systemische abgabe von proteinen einschliesslich mitglieder der tgf-superfamilie
EP2396025A2 (de) * 2009-02-12 2011-12-21 Stryker Corporation Periphere verabreichung von proteinen einschliesslich mitglieder der tgf-beta-superfamilie zur systemischen behandlung von störungen und erkrankungen
JP5749659B2 (ja) 2009-03-12 2015-07-15 ハーゼ インベストメンツ ウーゲー Ｂｍｐアンタゴニスト感受性が低下した骨形成タンパク質２（ｂｍｐ２）変異体
WO2010144696A1 (en) 2009-06-11 2010-12-16 Burnham Institute For Medical Research Directed differentiation of stem cells
US20110224410A1 (en) 2009-09-17 2011-09-15 Hile David Buffers for Controlling the pH of Bone Morphogenetic Proteins
JP2013514811A (ja) 2009-12-22 2013-05-02 ストライカー コーポレイション 免疫原性が抑制されたｂｍｐ−７変異体
CN101822815A (zh) * 2010-04-29 2010-09-08 广东八加一医药有限公司 系列多肽小分子在制备防治缺血性脑血管疾病药物中的应用
US9688735B2 (en) 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
EP2949338B1 (de) 2010-08-20 2017-10-25 Wyeth LLC Osteogene designerproteine
US9700596B2 (en) 2011-03-04 2017-07-11 The Regents Of The University Of California Locally released growth factors to mediate motor recovery after stroke
KR101274930B1 (ko) * 2011-06-03 2013-06-17 전남대학교산학협력단 골 형성 또는 혈관신생 촉진용 펩타이드 ｂｆｐ 4 및 이의 용도
CN106478776A (zh) * 2011-07-19 2017-03-08 特拉索斯创新公司 抗纤维化肽及其在用于治疗以纤维化为特征的疾病和病症的方法中的用途
EP2784083A1 (de) 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Knochenmorphogenetische Protein (BMP)-Varianten mit hoch reduzierter Antagonisten-Sensibilität und erweiterter spezifischer biologischer Aktivität
CA2911514A1 (en) 2013-05-06 2014-11-13 Scholar Rock, Inc. Compositions and methods for growth factor modulation
EP3543339A1 (de) 2015-02-13 2019-09-25 Factor Bioscience Inc. Nukleinsäureprodukte und verabreichungsverfahren dafür
IL264439B1 (en) 2016-08-17 2024-04-01 Factor Bioscience Inc A suitable viral preparation containing a synthetic messenger RNA encoding a gene editing protein for use in cancer treatment and a synthetic messenger RNA encoding a gene editing protein for use in therapy
BR112021000018A2 (pt) * 2018-07-03 2021-07-06 Venturis Therapeutics Inc composições e métodos para tratamento de acidente vascular cerebral
EP4154001A4 (de) * 2020-05-19 2024-06-05 Elevian Inc Verfahren und zusammensetzungen zur behandlung von schlaganfall

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440860A (en) 1980-01-18 1984-04-03 The Children's Medical Center Corporation Stimulating cell growth
US4296100A (en) 1980-06-30 1981-10-20 Franco Wayne P Method of treating the heart for myocardial infarction
US4378347A (en) * 1980-06-30 1983-03-29 Franco Wayne P Composition for treating the heart for myocardial infarction
DE3110560A1 (de) 1981-03-18 1982-10-14 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen "angiotropine der leukozyten und des entzuendungsgewebes: eine neue klasse natuerlicher chemotropischer mitogene fuer das richtungswachstum von blutgefaessen und zur neovaskularisierung von geweben"
EP0105014B1 (de) 1982-09-24 1992-05-20 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Wiederherstellung von Gewebe bei Tieren
US4806523A (en) 1985-08-06 1989-02-21 Collagen Corporation Method of treating inflammation
US4971952A (en) 1986-03-06 1990-11-20 Collagen Corporation Method of treating inflammation with cartilage inducing factor
US4994559A (en) * 1985-12-17 1991-02-19 Synergen, Inc. Human basic fibroblast growth factor
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Factors that soak bone formation
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4861757A (en) 1986-11-14 1989-08-29 Institute Of Molecular Biology Wound healing and bone regeneration using PDGF and IGF-I
EP0269408A3 (de) 1986-11-26 1989-08-30 Genentech, Inc. TGF-Beta für die Behandlung von entzündlichen Erkrankungen
US4797277A (en) 1987-09-22 1989-01-10 Pharmacia Ab Method for reperfusion therapy
US5011691A (en) 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5108753A (en) 1988-04-08 1992-04-28 Creative Biomolecules Osteogenic devices
JPH0262829A (ja) 1988-05-18 1990-03-02 Nippon Kayaku Co Ltd 虚血に基づく傷害の予防及び治療剤
US4983581A (en) 1988-05-20 1991-01-08 Institute Of Molecular Biology, Inc. Wound healing composition of IGF-I and TGF-β
HU201095B (en) 1988-06-14 1990-09-28 Richter Gedeon Vegyeszet New peptides inhibiting the activity of the immune system and pharmaceutical compositions comprising same, as well as process for producing these peptides and compositions
EP0423206A1 (de) 1988-07-08 1991-04-24 University College London Analyse von zellmodifizierenden substanzen
AU4056089A (en) 1988-07-20 1990-02-19 Amgen, Inc. Method of treating inflammatory disorders by reducing phagocyte activation
US5057494A (en) 1988-08-03 1991-10-15 Ethicon, Inc. Method for preventing tissue damage after an ischemic episode
US5106626A (en) 1988-10-11 1992-04-21 International Genetic Engineering, Inc. Osteogenic factors
US5135915A (en) 1988-10-14 1992-08-04 Genentech, Inc. Method for the treatment of grafts prior to transplantation using TGF-.beta.
US5011914A (en) 1989-01-05 1991-04-30 Collins Franklin D Purified ciliary neurotrophic factor
US5002965A (en) 1989-05-09 1991-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Use of ginkgolides to prevent reperfusion injury in organ transplantation
US5118791A (en) 1989-05-25 1992-06-02 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
IL97365A0 (en) * 1991-02-27 1992-05-25 Yeda Res & Dev Pharmaceutical compositions comprising a lymphokine
US5158934A (en) 1989-09-01 1992-10-27 Genentech, Inc. Method of inducing bone growth using TGF-β
DK0448704T3 (da) 1989-10-17 1999-04-06 Stryker Corp Osteogene anordninger
US5108989A (en) 1990-04-04 1992-04-28 Genentech, Inc. Method of predisposing mammals to accelerated tissue repair
ES2137931T3 (es) 1990-06-15 2000-01-01 Carnegie Inst Of Washington Proteinas gdf-1 y uog-1.
EP0550625B1 (de) 1990-09-26 2003-11-05 Genetics Institute, LLC Bmp-5-derivate
AU663689B2 (en) 1990-10-18 1995-10-19 Stryker Corporation Osteogenic peptides
CA2096441A1 (en) 1990-11-16 1992-05-17 Celtrix Pharmaceuticals, Inc. Heterodimer of b-type transforming growth factors 2 and 3
CA2097063C (en) 1990-11-27 2006-08-08 Howard P. Greisler Tissue sealant and growth factor containing compositions that promote accelerated wound healing
AU651421B2 (en) 1990-11-30 1994-07-21 Celtrix Pharmaceuticals, Inc. Use of a bone morphogenetic protein in synergistic combination with TGF-beta for bone repair
WO1992015323A1 (en) * 1991-03-11 1992-09-17 Creative Biomolecules, Inc. Protein-induced morphogenesis
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
AU662155B2 (en) 1991-05-10 1995-08-24 Celtrix Pharmaceuticals, Inc. Targeted delivery of bone growth factors
JPH06500574A (ja) 1991-05-10 1994-01-20 ザ　ソーク　インスティテュート　フォア　バイオロジカル　スタディーズ アクチビン／ＴＧＦ―βスーパーファミリーのレセプターのクローニングおよび組換えによる産生
ATE142460T1 (de) 1991-06-21 1996-09-15 Genetics Inst Osteogene proteine enthaltende arzneimittel
ATE175441T1 (de) 1991-06-25 1999-01-15 Genetics Inst Bmp-9 zusammensetzungen
EP0601106B2 (de) * 1991-08-30 2003-11-05 Curis, Inc. Morphogen-induzierte Modulation von entzündlichen Antworten
EP0825442A3 (de) 1991-08-30 2004-02-11 Curis, Inc. Screeningverfahren von morphogenischen Proteinen
EP0601135B1 (de) 1991-08-30 2005-11-02 Curis, Inc. Osteogenische proteine in der behandlung von metabolischen knochenkrankheiten
WO1993009229A1 (en) 1991-11-04 1993-05-13 Genetics Institute, Inc. Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
US5733871A (en) * 1991-11-08 1998-03-31 The General Hospital Corporation Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
DK0625050T3 (da) * 1991-11-22 1999-10-25 Auckland Uniservices Ltd TGF-BETA til forbedring af regenerering af nervevæv
DE19525416A1 (de) † 1995-07-12 1997-01-16 Bioph Biotech Entw Pharm Gmbh Verwendung von MP52 zur Behandlung und Prävention von Erkrankungen des Nervensystems
ATE242639T1 (de) 1992-07-31 2003-06-15 Curis Inc Morphogen induzierte nerven wiederherstellung und wiedergutmachung.
ES2061380B1 (es) * 1992-11-23 1995-07-01 Boehringer Ingelheim Espana Empleo del factor de crecimiento fibroblastico y sus derivados como neuroprotectores y neuromoduladores.
WO1995005846A1 (en) † 1993-08-26 1995-03-02 Genetics Institute, Inc. Neural regeneration using human bone morphogenetic proteins
AU7605394A (en) 1993-09-03 1995-03-22 Regents Of The University Of California, The Neural tissue affecting factor and compositions
DE69434934D1 (de) 1993-10-14 2007-04-12 Harvard College Verfahren zur induzierung und zur erhaltung neuronalen zellen
WO1995024474A1 (en) 1994-03-10 1995-09-14 Human Genome Sciences, Inc. Bone morphogenic protein-10
WO1998020889A1 (en) * 1996-11-15 1998-05-22 Creative Biomolecules Inc Morphogen peptide-induced regeneration of sense perceptory tissues

Also Published As

Publication number Publication date
AU725341B2 (en) 2000-10-12
CA2249596C (en) 2011-11-08
AU2552997A (en) 1997-10-10
DE69723429T3 (de) 2007-09-20
US20030022830A1 (en) 2003-01-30
US20010039261A1 (en) 2001-11-08
ATE493141T1 (de) 2011-01-15
CA2249596A1 (en) 1997-09-25
AU734312B2 (en) 2001-06-07
WO1997034626A1 (en) 1997-09-25
DE69740089D1 (de) 2011-02-10
JP2000507939A (ja) 2000-06-27
ES2201287T5 (es) 2007-10-16
US6407060B1 (en) 2002-06-18
AU2582397A (en) 1997-10-10
EP0894004A1 (de) 1999-02-03
EP0904093A1 (de) 1999-03-31
ES2201287T3 (es) 2004-03-16
EP1364655B1 (de) 2010-12-29
JP4847634B2 (ja) 2011-12-28
EP0904093A4 (de) 2004-11-17
DE69723429T2 (de) 2004-04-22
KR20000064752A (ko) 2000-11-06
WO1997034618A1 (en) 1997-09-25
US6214796B1 (en) 2001-04-10
CN1181885C (zh) 2004-12-29
CN1219133A (zh) 1999-06-09
JP2000506894A (ja) 2000-06-06
EP1364655A1 (de) 2003-11-26
DE69723429D1 (de) 2003-08-14
EP0894004B2 (de) 2007-02-21
EP0894004B1 (de) 2003-07-09
CA2249368A1 (en) 1997-09-25

Similar Documents

Publication Publication Date Title
ATE244574T1 (de) Verfahren zur verbesserten funktionelle erholung der motorische koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns
DE3587266D1 (de) Verfahren und system zur entfernung von immunosuppressiven bestandteilen aus saeugetierblut.
ATE140388T1 (de) Zusammensetzungen enthaltend omega conotoxin peptide derivate und deren verwendung zur behandlung von ischämie-artigen neuronalen schädigungen
ATE258067T1 (de) Kombinationspräparat zur behandlung der parkinsonschen krankheit, das selektive nmda- antagonisten enthält
EP0464932A3 (en) Inhibition of wasting and protein degradation of mammalian muscle by tetracyclines
DE69232287D1 (de) Verfahren und zusammensetzung zur verminderung von reperfusionsschäden des myokards
FI943028A0 (fi) Happoa kestävä FGF-koostumus ja menetelmä ruoansulatuskanavassa esiintyvien, haavaumia aiheuttavien sairauksien hoitamiseksi
DE3878627D1 (de) Zusammensetzung zur oberflaechenbehandlung von kautschuk.
DE69316013T2 (de) Verwendung von phosphinate zur behandlung der osteoporose
DE69638281D1 (de) Anti-Interleukin-9 Antikörper oder Anti-Interleukin-9 Rezeptor Antikörper zur Behandlung von bronchialem Hyperreaktionsvermögen
DE69625682D1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
EP0577025A3 (de) Angiotensin-II-Rezeptorantagonisten zur Behandlung und Prophylaxe von koronaren Herzerkrankungen
ATE238793T1 (de) Verfahren zur förderung von ovulation und geburt bei säugetieren
EP0435177A3 (en) 4-benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
DE69924483D1 (de) Kombinationstherapie zur behandlung von tumoren
BG102716A (en) Method for the treatment of cardiac insufficiency by means of formulations opposing the endotheline
PH24094A (en) 5-aryl-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
Baines et al. Selective activity of a proctolin analogue reveals the existence of two receptor subtypes
ATE167628T1 (de) Verfahren und zusammensetzungen zur behandlung von krankheiten verbunden mit mangelhaften immunfunktion
EP0116628A4 (de) 1-acyl-3-pyridylmethylguanidine und deren verwendung als antihypertensiva.
ZA873928B (en) Topical methotrexate preparation for the treatment of hyperproliferative epithelial disease
DE3479477D1 (en) A pharmaceutical composition for use in treating neurological disease or aging
ATE44751T1 (de) Zusammensetzungen zum behandeln von ischaemie im gehirn.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties